796 related articles for article (PubMed ID: 29087303)
41. SWI/SNF Complex-deficient Undifferentiated Carcinoma of the Gastrointestinal Tract: Clinicopathologic Study of 30 Cases With an Emphasis on Variable Morphology, Immune Features, and the Prognostic Significance of Different SMARCA4 and SMARCA2 Subunit Deficiencies.
Chang B; Sheng W; Wang L; Zhu X; Tan C; Ni S; Weng W; Huang D; Wang J
Am J Surg Pathol; 2022 Jul; 46(7):889-906. PubMed ID: 34812766
[TBL] [Abstract][Full Text] [Related]
42. High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer.
Guerrero-Martínez JA; Reyes JC
Sci Rep; 2018 Feb; 8(1):2043. PubMed ID: 29391527
[TBL] [Abstract][Full Text] [Related]
43. Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden.
Naito T; Udagawa H; Umemura S; Sakai T; Zenke Y; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuboi M; Ishii G; Goto K
Lung Cancer; 2019 Dec; 138():35-42. PubMed ID: 31630044
[TBL] [Abstract][Full Text] [Related]
44. Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in
Zundell JA; Fukumoto T; Lin J; Fatkhudinov N; Nacarelli T; Kossenkov AV; Liu Q; Cassel J; Hu CA; Wu S; Zhang R
Cancer Res; 2021 Oct; 81(20):5325-5335. PubMed ID: 34548333
[TBL] [Abstract][Full Text] [Related]
45. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Ler LD; Ghosh S; Chai X; Thike AA; Heng HL; Siew EY; Dey S; Koh LK; Lim JQ; Lim WK; Myint SS; Loh JL; Ong P; Sam XX; Huang D; Lim T; Tan PH; Nagarajan S; Cheng CW; Ho H; Ng LG; Yuen J; Lin PH; Chuang CK; Chang YH; Weng WH; Rozen SG; Tan P; Creasy CL; Pang ST; McCabe MT; Poon SL; Teh BT
Sci Transl Med; 2017 Feb; 9(378):. PubMed ID: 28228601
[TBL] [Abstract][Full Text] [Related]
46. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
47. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
[TBL] [Abstract][Full Text] [Related]
48. SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca
Xue Y; Morris JL; Yang K; Fu Z; Zhu X; Johnson F; Meehan B; Witkowski L; Yasmeen A; Golenar T; Coatham M; Morin G; Monast A; Pilon V; Fiset PO; Jung S; Gonzalez AV; Camilleri-Broet S; Fu L; Postovit LM; Spicer J; Gotlieb WH; Guiot MC; Rak J; Park M; Lockwood W; Foulkes WD; Prudent J; Huang S
Nat Commun; 2021 Sep; 12(1):5404. PubMed ID: 34518526
[TBL] [Abstract][Full Text] [Related]
49. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
50. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
[TBL] [Abstract][Full Text] [Related]
51. Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers.
Sasaki M; Kato D; Murakami K; Yoshida H; Takase S; Otsubo T; Ogiwara H
Nat Commun; 2024 Jun; 15(1):4770. PubMed ID: 38839769
[TBL] [Abstract][Full Text] [Related]
52. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
[TBL] [Abstract][Full Text] [Related]
53. Targeting epigenetics in sarcomas through EZH2 inhibition.
Italiano A
J Hematol Oncol; 2020 Apr; 13(1):33. PubMed ID: 32264965
[TBL] [Abstract][Full Text] [Related]
54. Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.
Papillon JPN; Nakajima K; Adair CD; Hempel J; Jouk AO; Karki RG; Mathieu S; Möbitz H; Ntaganda R; Smith T; Visser M; Hill SE; Hurtado FK; Chenail G; Bhang HC; Bric A; Xiang K; Bushold G; Gilbert T; Vattay A; Dooley J; Costa EA; Park I; Li A; Farley D; Lounkine E; Yue QK; Xie X; Zhu X; Kulathila R; King D; Hu T; Vulic K; Cantwell J; Luu C; Jagani Z
J Med Chem; 2018 Nov; 61(22):10155-10172. PubMed ID: 30339381
[TBL] [Abstract][Full Text] [Related]
55. Polycomb Repressive Complex 2 Confers BRG1 Dependency on the CIITA Locus.
Abou El Hassan M; Yu T; Song L; Bremner R
J Immunol; 2015 May; 194(10):5007-13. PubMed ID: 25862816
[TBL] [Abstract][Full Text] [Related]
56. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
57. Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.
Abou-Taleb H; Yamaguchi K; Matsumura N; Murakami R; Nakai H; Higasa K; Amano Y; Abiko K; Yoshioka Y; Hamanishi J; Koshiyama M; Baba T; Yamada R; Matsuda F; Konishi I; Mandai M
Oncotarget; 2016 Aug; 7(34):54758-54770. PubMed ID: 27340867
[TBL] [Abstract][Full Text] [Related]
58. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
[TBL] [Abstract][Full Text] [Related]
59. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
[TBL] [Abstract][Full Text] [Related]
60. Targeting EZH2 in cancer therapy.
Yamagishi M; Uchimaru K
Curr Opin Oncol; 2017 Sep; 29(5):375-381. PubMed ID: 28665819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
